Fosun Pharma: The indication for Vimiglumine Capsules has been approved for addition.

Fosun Pharmaceutical announced that its controlling subsidiary Jinzhou Aohong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the new indication of Venetoclax Capsules in the treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients: in combination with aromatase inhibitors as initial endocrine therapy.